Report Summary
Clinical trials market now witness a paradigm shift. NaA¯ve heterogeneous patient populations in the developing nations is opening up new avenues for the clinical trials market. Developing countries also offer faster go to market which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the Pharma-Biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted
Browse all : Market Research Reports
Today, emerging countries account for the largest share of the phase II/III (prime stages) clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic and cardiovascular diseases. Support from the respective government bodies is one of the major factors affecting the clinical trials market. Clinical trials sponsored by the industry have a much higher share in the market as compared to government organizations.
The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare, PPD, Parexel, Kendle and Quintles.
This research report categorizes the Global Clinical Trials Market on the basis of phases, indications, and study design analyzing trends in each. Each section will provide market data, market drivers, trends and opportunities, key players, and competitive outlook. This report will also provide more than 20 company profiles.
Table of Contents
1 Introduction
1.1 Key Take-aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
2 Executive Summary
2.1 Overview of the Market
2.2 Key Findings
3 Market Overview
3.1 Market Definition
3.2 Drivers
3.2.1 Globalizing drug development activities
3.2.2 Rise in r&d investments expected to boost the clinical trials market
3.2.3 High disease prevalence in emerging countries
3.3 Restraints
3.3.1 Longer approval time for clinical trials – a cause of concern for major pharmaceutical-biotechnology players
3.4 Burning Issues
3.4.1 Out skirting boundaries of medical ethics
3.5 Winning Imperatives
3.5.1 Leveraging online resources to increase patient recruitment rates in clinical trials
3.6 Country Comparison
3.7 Industry Trends
3.7.1 Engaging clinical trials in emerging countries & low cost CRO’s prove to be compelling options in times of drug patent expiry
3.7.2 CROs leveraging the benefits of emerging markets
3.7.3 Changing CRO business models
3.7.3.1 Full service model
3.7.3.2 Hourly billing model
3.7.3.3 Full time equivalent model (FTE)
3.7.3.4 Fixed price model
3.7.4 Prevalence of preferred provider relationships
3.7.5 Shift towards patient centric clinical trials due to technical advances
3.8 Global Clinical Trials Market
3.8.1 Offshoring & outsourcing
4 Clinical Trials Market, by Types
4.1 Introduction
4.1.1 Clinical trials market, by study phases
4.1.1.1 Preclinical studies
4.1.1.2 Phase I trials
4.1.1.3 Phase II trials
4.1.1.4 Phase I/II
4.1.1.5 Phase II/III
4.1.1.6 Phase III trials
4.1.2 Clinical trials market, by study designs
4.1.2.1 Observational studies
4.1.2.2 Interventional studies
4.1.2.3 Expanded access trials
4.1.3 Clinical trials market, by indications
5 Geographic Analysis
5.1 North America
5.1.1 U.S.
5.1.1.1 Regulatory environment
5.1.1.2 Clinical trials registry
5.1.1.3 Government support
5.1.2 Canada
5.1.2.1 Regulatory environment
5.1.2.2 Clinical trials registry
5.1.2.3 Government support
5.2 Europe
5.2.1 UK
5.2.1.1 Regulatory environment
5.2.1.2 Clinical trials registry
5.2.1.3 Government support
5.2.2 Germany
5.2.2.1 Regulatory environment
5.2.2.2 Clinical trials registry
5.2.2.3 Government support
5.2.3 Italy
5.2.3.1 Regulatory environment
5.2.3.2 Clinical trials registry
5.2.3.3 Government support
5.2.4 France
5.2.4.1 Regulatory environment
5.2.4.2 Clinical trials registry
5.2.4.3 Support rendered by the government
5.2.5 Spain
5.2.5.1 Regulatory environment
5.2.5.2 Clinical trials registry
5.2.5.3 Government support
5.2.6 Poland
5.2.6.1 Regulatory environment
5.2.6.2 Clinical trials registry
5.2.6.3 Support rendered by the Government
5.2.7 Russia
5.2.7.1 Regulatory environment
5.2.7.2 Clinical trials registry
5.2.7.3 Support rendered by the Government
5.2.8 Turkey
5.2.8.1 Regulatory environment
5.2.8.2 Clinical trials registry
5.2.8.3 Government support
5.2.9 Ukraine
5.2.9.1 Regulatory environment
5.2.9.2 Clinical trials registry
5.2.9.3 Support rendered by the Government
5.3 Asia
5.3.1 China
5.3.1.1 Clinical trials registry
5.3.1.2 Government support
5.3.2 India
5.3.2.1 Regulatory environment
5.3.2.2 Clinical trials registry
5.3.2.3 Government support
5.3.3 South Korea
5.3.3.1 Regulatory environment
5.3.3.2 Clinical trials registry
5.3.3.3 Government support
5.4 Latin America
5.4.1 Brazil
5.4.1.1 Regulatory environment
5.4.1.2 Clinical trials registry
5.4.1.3 Government support
5.4.2 Mexico
5.4.2.1 Regulatory environment
5.4.2.2 Clinical trials registry
5.4.2.3 Government support
5.4.3 Argentina
5.4.3.1 Regulatory environment
5.4.3.2 Clinical trials registry
5.4.3.3 Government support
6 Competitive Landscape
6.1 Introduction
Related Reports:
Clinical Trial Recruitment in Dermatology – Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers – http://www.reportsnreports.com/reports/130633-clinical-trial-recruitment-in-dermatology-most-trials-focus-on-.html
